PCM
ANAB icon

Penserra Capital Management’s AnaptysBio ANAB Stock Holding History

Penserra Capital Management’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-43,430
Closed -$2.41M – 1108
2026
Q1 		$2.41M Sell
43,430
-12,922
-23% -$695K 0.03% 324
2025
Q4 		$2.73M Buy
+56,352
New +$2.2M 0.03% 318
2021
Q4 		– Sell
-630
Closed -$17K – 1363
2021
Q3 		$17K Buy
630
+5
+0.8% +$127 ﹤0.01% 1272
2021
Q2 		$16K Buy
625
+10
+2% +$240 ﹤0.01% 1194
2021
Q1 		$13K Sell
615
-15
-2% -$379 ﹤0.01% 1004
2020
Q4 		$13K Buy
630
+398
+172% +$9.66K ﹤0.01% 896
2020
Q3 		$3K Buy
+232
New +$4.19K ﹤0.01% 881

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Penserra Capital Management's ANAB Position: Q2 2026 in Review

Penserra Capital Management sold out of AnaptysBio (ANAB) in Q2 2026, closing a stake of 43,430 shares — an estimated $2.41M sold.

Penserra Capital Management first reported a position in ANAB in Q3 2020 and held it in 7 quarters. The position peaked at $2.73M in Q4 2025. 213 funds tracked by Wall St. Rank hold ANAB as of Q2 2026.

  • Penserra Capital Management reported no remaining AnaptysBio position as of Q2 2026 after selling out during the quarter.
  • Penserra Capital Management sold 43,430 AnaptysBio shares in Q2 2026, an estimated $2.41M.
  • Penserra Capital Management first reported a position in AnaptysBio in Q3 2020 and held it in 7 quarters.
  • Penserra Capital Management's AnaptysBio position peaked at $2.73M in Q4 2025.
  • 213 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2026.

Based on Penserra Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.